1. The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial.
- Author
-
Arnold, D T, Hooper, C E, Morley, A, White, P, Lyburn, I D, Searle, J, Darby, M, Hall, T, Hall, D, Rahman, N M, De Winton, E, Clive, A, Masani, V, Dangoor, A, Guglani, S, Jankowska, P, Lowndes, S A, Harvey, J E, Braybrooke, J P, and Maskell, N A
- Subjects
- *
PLEURA cancer , *MESOTHELIOMA , *CANCER chemotherapy , *CISPLATIN , *QUALITY of life , *CARBOPLATIN , *PLEURODESIS , *CANCER treatment , *THERAPEUTICS - Abstract
Background:The effect of chemotherapy on health-related quality of life (HRQoL) in malignant pleural mesothelioma (MPM) is poorly understood. Patient-individualised prognostication and prediction of treatment response from chemotherapy is useful but little evidence exists to guide practice.Method:Consecutive patients with MPM who were fit for first-line chemotherapy with pemetrexed and cisplatin\carboplatin were recruited and followed up for a minimum of 12 months. This study focussed on the HRQoL outcomes of these patients using the EQ-5D, EORTC QLQ-C30 and LC13.Results:Seventy-three patients were recruited of which 58 received chemotherapy and 15 opted for best supportive care (BSC). Compliance with HRQoL questionnaires was 98% at baseline. The chemotherapy group maintained HRQoL compared with the BSC group whose overall HRQoL fell (P=0.006) with worsening dyspnoea and pain. The impact of chemotherapy was irrespective of histological subtype although those with non-epithelioid disease had worse HRQoL at later time points (P=0.012). Additionally, those with a falling mesothelin or improvement on modified-RECIST CT at early follow-up had a better HRQoL at 16 weeks.Conclusions:HRQoL was maintained following chemotherapy compared with a self-selected BSC group. Once chemotherapy is initiated, a falling mesothelin or improved RECIST CT findings infer a quality-of-life advantage. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF